

Attachment 3: List of Nationally Notifiable Conditions

| <b>Nationally Notifiable Conditions in NNDSS Application</b> |
|--|
| <i>Anaplasma phagocytophilum</i>                             |
| Anthrax  |
| Babesiosis   |
| Botulism   |
| Brucellosis  |
| Campylobacteriosis   |
| Central line associated bloodstream infection                |
| Chancroid  |
| Chlamydia trachomatis infection                              |
| Cholera (toxigenic <i>Vibrio cholerae</i> O1 or O139)        |
| Coccidioidomycosis   |
| Cryptosporidiosis  |
| Cyclosporiasis   |
| Diphtheria   |
| <i>Ehrlichia chaffeensis</i>                                 |
| <i>Ehrlichia ewingii</i>                                     |
| Ehrlichiosis/Anaplasmosis, undetermined                      |
| Free-living amoeba infections                                |
| Giardiasis   |
| Gonorrhea  |
| <i>Haemophilus influenzae</i> , invasive disease             |
| Hansen disease (Leprosy)                                     |

Attachment 3: List of Nationally Notifiable Conditions

|   |
|---|
| Hantavirus pulmonary syndrome                             |
| Hemolytic uremic syndrome postdiarrheal                   |
| Hepatitis A, acute  |
| Hepatitis B virus infection, chronic                      |
| Hepatitis B, acute  |
| Hepatitis B, virus infection perinatal                    |
| Hepatitis C   |
| Hepatitis E, acute  |
| Influenza-associated pediatric mortality                  |
| <i>Invasive Pneumococcal Disease (IPD)</i>                |
| Legionellosis   |
| Leptospirosis   |
| Listeriosis   |
| Lyme disease  |
| Malaria   |
| Measles   |
| Melioidosis   |
| Meningococcal disease (Neisseria meningitidis)            |
| Mumps   |
| Novel influenza A virus infections, initial detections of |
| Pertussis   |
| Plague  |

Attachment 3: List of Nationally Notifiable Conditions

|   |
|---|
| Poliomyelitis, paralytic  |
| Poliovirus infection, nonparalytic  |
| Psittacosis (Ornithosis)  |
| Q fever, acute  |
| Q fever, chronic  |
| Rabies, animal  |
| Rabies, human   |
| Rubella   |
| Rubella, congenital syndrome  |
| Salmonellosis   |
| Severe Acute Respiratory Syndrome (SARS)-associated<br>Coronavirus disease (SARS-CoV) |
| Shiga toxin-producing Escherichia coli (STEC)   |
| Shigellosis   |
| Smallpox  |
| Spotted Fever Rickettsiosis   |
| Streptococcal toxic-shock syndrome  |
| Syphilis  |
| Tetanus   |
| Toxic-shock syndrome (staphylococcal)   |
| Trichinellosis  |
| Tularemia   |
| S. Typhi infection  |

Attachment 3: List of Nationally Notifiable Conditions

|  |
|--|
| Vancomycin-intermediate Staphylococcus aureus (VISA)                     |
| Vancomycin-resistant Staphylococcus aureus (VRSA)                        |
| Varicella (Chickenpox)   |
| Vibriosis (non-cholera Vibrio species infections)                        |
| Viral hemorrhagic fevers   |
| Hantavirus infection, non-Hantavirus Pulmonary Syndrome                  |
| Arboviral diseases   |
| <i>Candida auris</i>   |
| Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) |
| Tuberculosis (TB) Disease  |
| Carbon Monoxide Poisoning  |
| S. Paratyphi infection   |
| 2019 Novel Coronavirus Disease (COVID-19)                                |